Who Generates More Revenue? argenx SE or ADMA Biologics, Inc.

Argenx SE leads revenue growth over ADMA Biologics by 2023.

__timestampADMA Biologics, Inc.argenx SE
Wednesday, January 1, 201459155454579319.93
Thursday, January 1, 201571776337504448.39
Friday, January 1, 20161066103715466459
Sunday, January 1, 20172276056043793829
Monday, January 1, 20181698529024564806
Tuesday, January 1, 20192934908378116087
Wednesday, January 1, 20204221978344848173
Friday, January 1, 202180942625497277000
Saturday, January 1, 2022154079692410746000
Sunday, January 1, 20232582149991226316000
Loading chart...

Unleashing the power of data

Revenue Race: Argenx SE vs. ADMA Biologics, Inc.

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Argenx SE and ADMA Biologics, Inc. have been vying for dominance. From 2014 to 2023, Argenx SE has consistently outpaced ADMA Biologics, with a staggering 1,226% increase in revenue by 2023. In contrast, ADMA Biologics saw a respectable growth of 336% during the same period.

A Decade of Growth

In 2014, both companies started with modest revenues, but by 2023, Argenx SE's revenue soared to over four times that of ADMA Biologics. This remarkable growth trajectory highlights Argenx SE's strategic advancements and market positioning. As the biotech industry continues to evolve, these companies exemplify the dynamic nature of revenue generation and market competition.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025